Sitagliptin and the risk of hospitalization for heart failure: A population-based study

International Journal of Cardiology

Volumn 177, Issue 1, 2014, Pages 86-90

  Wang, Kang Ling ^a,b   Liu, Chia Jen ^a,b   Chao, Tze Fan ^a,b   Huang, Chi Ming ^b   Wu, Cheng Hsueh ^a,b   Chen, Su Jung ^a,b   Yeh, Chiu Mei ^a   Chen, Tzeng Ji ^a,b   Lin, Shing Jong ^a,b   Chiang, Chern En ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Sitagliptin Heart failure Outcome research

Indexed keywords

SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; COMPLICATION; HEALTH SURVEY; MIDDLE AGED; MORBIDITY; PROCEDURES; PROPENSITY SCORE; RISK FACTOR; TAIWAN; TRENDS;

DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MORBIDITY; POPULATION SURVEILLANCE; PROPENSITY SCORE; PYRAZINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TRIAZOLES;

EID: 84909956991     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.09.038     Document Type: Article

References (30)

1. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
2. S.R. Seshasai, S. Kaptoge, A. Thompson, E. Di Angelantonio, P. Gao, and N. Sarwar Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 364 2011 829 841
3. R.G. Dluhy, and G.T. McMahon Intensive glycemic control in the ACCORD and ADVANCE trials N Engl J Med 358 2008 2630 2633
4. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
5. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
6. P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, and N.P. Jones Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 357 2007 28 38
7. H.R. Patil, F.J. Al Badarin, H.A. Al Shami, S.K. Bhatti, C.J. Lavie, and D.S. Bell Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 110 2012 826 833
8. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
9. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 2013 1327 1335
10. S.H. Golden Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications Am J Cardiol 108 2011 59B 67B
11. O. Mosenzon, and I. Raz Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials Eur Heart J Suppl 14 2012 B22 B29
12. P.H. Joshi, R.R. Kalyani, R.S. Blumenthal, and T.W. Donner Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data Am J Cardiol 110 2012 32B 42B
13. J.B. Green, M.A. Bethel, S.K. Paul, A. Ring, K.D. Kaufman, and D.R. Shapiro Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease Am Heart J 166 2013 983-9 e7
14. J. Rosenstock, N. Marx, S.E. Kahn, B. Zinman, J.J. Kastelein, and J.M. Lachin Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial Diab Vasc Dis Res 10 2013 289 301
15. V. Lo Re III, K. Haynes, E.E. Ming, J. Wood Ives, L.N. Horne, and K. Fortier Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies Pharmacoepidemiol Drug Saf 21 2012 1202 1215
16. K.L. Wang, C.J. Liu, T.F. Chao, C.M. Huang, C.H. Wu, and S.J. Chen Statins, risk of diabetes, and implications on outcomes in the general population J Am Coll Cardiol 60 2012 1231 1238
17. C.S. Gau, I.S. Chang, F.L. Lin Wu, H.T. Yu, Y.W. Huang, and C.L. Chi Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan Pharmacoepidemiol Drug Saf 16 2007 86 95
18. E.L. Sattler, J.S. Lee, and M. Perri III Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature Drugs Aging 30 2013 383 399
19. T.B. Horwich, and G.C. Fonarow Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure J Am Coll Cardiol 55 2010 283 293
20. A.M. From, C.G. Scott, and H.H. Chen The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study J Am Coll Cardiol 55 2010 300 305
21. A.J. Scheen Cardiovascular effects of gliptins Nat Rev Cardiol 10 2013 73 84
22. B. Gallwitz, J. Rosenstock, T. Rauch, S. Bhattacharya, S. Patel, and M. von Eynatten 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 380 2012 475 483
23. D.J. Hausenloy, and D.M. Yellon GLP-1 therapy: beyond glucose control Circ Heart Fail 1 2008 147 149
24. R. De Caterina, R. Madonna, H. Sourij, and T. Wascher Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options Eur Heart J 31 2010 1557 1564
25. A. Takahashi, M. Asakura, S. Ito, K.D. Min, K. Shindo, and Y. Yan Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice Am J Physiol Heart Circ Physiol 304 2013 H1361 H1369
26. N. Gomez, K. Touihri, V. Matheeussen, A. Mendes Da Costa, M. Mahmoudabady, and M. Mathieu Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure Eur J Heart Fail 14 2012 14 21
27. M. Sauve, K. Ban, M.A. Momen, Y.Q. Zhou, R.M. Henkelman, and M. Husain Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
28. M. Ayaori, N. Iwakami, H. Uto-Kondo, H. Sato, M. Sasaki, and T. Komatsu Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients J Am Heart Assoc 2 2013 e003277
29. I. Brandt, A.M. Lambeir, J.M. Ketelslegers, M. Vanderheyden, S. Scharpe, and I. De Meester Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form Clin Chem 52 2006 82 87
30. C.L. Cheng, Y.H. Kao, S.J. Lin, C.H. Lee, and M.L. Lai Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan Pharmacoepidemiol Drug Saf 20 2011 236 242